$OABI

OmniAb (OABI) reported Q3 2026 earnings, highlighting a new partnership with Lilly, which includes an upfront payment and up to $370M in potential milestone payments. The company saw increased utilization of its technologies and strong traction with its xPloration platform. OmniAb also launched OmniTides, a new peptide discovery offering. The company raised its 2026 revenue and cash outlook, and reported 111 active partners and 433 active programs as of Q3.

OmniAb reported 1Q 2026 revenue of $3.99M, up 78.3% YoY, with a net loss of $15.73M and EPS of ($0.12). Nine-month revenue rose 209% to $31.8M, driven by milestone revenue and growth in services and xPloration. Active partners and programs increased to 111 and 433, respectively.

OmniAb, Inc. (OABI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 OmniAb Reports Third Quarter 2026 Financial Results and Business Highlights Raises Full Year 2026 Revenue and Cash Outlook on Continued Business Momentum Conference Call to Begin Today at 8:00 a.m. ET EMERYVILLE, Calif. (October 30, 2026) – OmniAb, Inc. (NASDAQ: OABI

OmniAb (OABI) reported a $3B milestone pipeline at a conference, with 425 active partner programs. The company expects $2M-$3M in xPloration sales this year, doubling by 2027 and 2028. Partners include major pharma companies, with potential milestones exceeding $3B. OmniAb anticipates $32M-$36M in revenue for the year, with cash breakeven expected by year-end.

OmniAb (OABI) held an investor day, highlighting its royalty pipeline, the launch of OmniTides for peptide discovery, and the commercialization of xPloration. The company expects xPloration to generate $2M-$3M in 2026, doubling in 2027 and 2028. OmniAb reaffirmed 2026 revenue guidance of $32M-$36M and expects to be near cash-flow breakeven. The company discussed its licensing models, chicken-based discovery platforms, and ion-channel capabilities, including a partnership with Eli Lilly.

StoneX raised its price target for OmniAb (NASDAQ:OABI) to $6.00 from $4.00, citing new product launches and platform expansion. The stock is currently at $4.47, down 12% over the past week but up 164% over the last year. The company reported Q2 2026 earnings that exceeded expectations and raised its full-year outlook. Analysts maintain a Strong Buy consensus with price targets ranging from $5 to $11.

Stifel maintained a Buy rating and $9.00 price target for OmniAb (OABI), citing its technology platform and upcoming catalysts. The stock has fallen 12.3% in a week but risen 188% in six months. OmniAb reported Q2 2026 earnings beating estimates, with revenue of $13.41M vs. $4.95M expected.

OABI stock rose 10% today with $4.3M in trading volume. Insiders sold 33,314 shares in the past 6 months. 78 hedge funds increased holdings, while 66 decreased. Notable moves include Nomura Holdings adding 4.3M shares and Whitefort Capital Management removing 3.9M shares.

OmniAb, Inc. (NASDAQ: OABI) announced its Investor & Analyst Day on October 6, 2026, in Emeryville, CA. The event will feature presentations on corporate updates, technology innovations, and a Q&A session. Both in-person and virtual participation are available. OmniAb provides discovery research technology for next-generation therapeutics, licensing its platform to pharmaceutical and biotech companies.

OmniAb (OABI) +13% to $5.43, raising 2026 cash flow guidance to $49M-$53M. Freenome (FRNM) +4% to $16.03 after FDA approvals. Exelixis (EXEL) +$59.11, Q2 profit $212M. LifeStance (LFST) +$13.15, Q2 revenue +26% to $435.4M. Faeth (FTH) +$40.89, Q2 loss $16M.